Deans' stroke musings: Phylogica secures European patent for Phylomer peptides

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, April 24, 2013

Phylogica secures European patent for Phylomer peptides

I had not seen any previous clinical study articles on this and since this is a business article I don't know how good this might be.
http://www.proactiveinvestors.com.au/companies/news/42441/phylogica-secures-european-patent-for-phylomer-peptides--42441.html

Phylogica (ASX: PYC) has been granted a new European patent covering its lead Phylomer peptides for use in the treatment of ischemic disease, which is a restriction in blood supply to tissues.

The granted claims of the patent cover use of these Phylomers in important clinical settings such as stroke, traumatic brain injury and reperfusion injury of liver, heart and blood vessels following transplantation.

These particular Phylomer peptides target the AP‐1 pathway, which is a crucial mediator of inflammation and cell death in multiple diseases.

The AP‐1 pathway plays a critical role in neuronal cell death caused by stroke and traumatic brain injury, and lung inflammation resulting from acute respiratory distress syndrome (ARDS) and septic shock.

The peptides covered by this patent are active in this pathway and help to reduce the collateral damage to tissue.

The family of Phylomer peptides has demonstrated efficacy in multiple preclinical models for stroke, traumatic brain injury and ARDS.

More than half of the discovery alliances that Phylogica is currently negotiating with the pharmaceutical and biotechnology industry are focused on accessing the intracellular space.

The vast majority of therapeutic targets are found within cells, yet most of these targets are not tractable with conventional drugs.

The Phylomer platform could provide a unique source of next‐generation biological drugs that can penetrate cells and thus expand the potential target landscape.

Phylogica is currently working with Janssen, part of Johnson & Johnson, to exploit its capabilities in this field.

The company also recently engaged Bio‐Link to support its partnering efforts for the anti‐inflammatory Phylomers targeting the intracellular transcription factor AP1.